Neoadjuvant Therapy for HER2+ Early Breast Cancer

Video

Neoadjuvant Therapy for HER2+ Early Breast Cancer

  • A 53-year-old woman was referred to a breast surgeon after finding a mass in her left breast
    • PMH: unremarkable
    • FH: no history of cancer in first-degree relatives
    • PE: revealed a 6 X 5-cm, non-fixed mass in the left inferior breast without skin changes or nipple discharge, and palpable lymphadenopathy in the left axilla
    • ROS: clear
  • Mammogram confirmed a left-sided, poorly defined spiculated mass. Ultrasound shows a 5.3-cm solid mass and enlargement of 2 left axillary nodes with thickened cortex
  • Pathology results:
    • Core needle biopsy from the breast mass confirmed grade 3 invasive ductal carcinoma
      • ER—,PR—,HER2IHC 3+
      • FISH,HER2copy number, 15;HER2:CEP17 ratio, 7
    • Fine-needle aspiration of one left axillary lymph nodes was positive for carcinoma
  • Staging: T2bN1M0
Related Videos
Video 2 - "Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease"
Video 1 - "Patient Case: Pathology of Graft Versus Host Disease"
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content
Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

April 18th 2024
Article

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

FDA Accepts BLA for Dato-DXd in HR+/HER2– Breast Cancer

FDA Accepts BLA for Dato-DXd in HR+/HER2– Breast Cancer

April 2nd 2024
Article

The biologics license application from the FDA is supported by data from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in HR-positive, HER2-negative breast cancer.

Read More

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020
Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen

Familiarity Eases Tolerability Challenges With Newer ADCs in Breast Cancer

Familiarity Eases Tolerability Challenges With Newer ADCs in Breast Cancer

March 25th 2024
Article

In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.

Read More

Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer

Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer

March 20th 2024
Article

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.

Read More